Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia

Autor:	Dale L. Bixby, Lydia L. Benitez, Heather Fox, Patrick W. Burke, Sarah Choi, Amy Skyles, Bernard L. Marini, Ashley Crouch, Fares Alsawah, Anthony J. Perissinotti, Kristen Pettit
Rok vydání:	2019
Předmět:	0301 basic medicine Oncology medicine.medical_specialty T cell Biopsy Immunophenotyping 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Refractory Internal medicine Meningeal Neoplasms Medicine Combined Modality Therapy Neoplasm Humans Molecular Targeted Therapy Alemtuzumab Injections Spinal business.industry Hematology Middle Aged medicine.disease Blood Cell Count Leukemia 030104 developmental biology medicine.anatomical_structure Treatment Outcome Drug Resistance Neoplasm Leukemia Prolymphocytic T-Cell Retreatment T-cell prolymphocytic leukemia Female Exceptional Case Report business 030215 immunology medicine.drug
Zdroj:	Blood advances. 3(21)
ISSN:	2473-9537
Popis:	Key Points This is the first report of successful treatment of therapy-resistant leptomeningeal T-PLL with intrathecal alemtuzumab. Intrathecal alemtuzumab is a potentially safe and efficacious therapeutic alternative for treatment of leptomeningeal T-PLL.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b1fdff769652eef09d7d173928cdde3 https://pubmed.ncbi.nlm.nih.gov/31698446 Zobrazit plný text záznamu